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Abstract
The aim of this study was to investigate travel-associated morbidity in European travellers in 2009 in comparison with 2008, with a par-
ticular emphasis on emerging infectious diseases with the potential for introduction into Europe. Diagnoses with demographic, clinical
and travel-related predictors of disease from ill returning travelers presenting to 12 core EuroTravNet sites from January to December
2009 were analysed. A total of 6392 patients were seen at EuroTravNet core sites in 2009, as compared with 6957 in 2008. As compared
with 2008, there was a marked increase in the number of travellers exposed in North America and western Europe. Respiratory illnesses,
in particular pandemic A(H1N1) inﬂuenza, inﬂuenza-like syndromes, and tuberculosis, were also observed more frequently. A signiﬁcant
increase in reported dengue cases in 2009 as compared with 2008 was observed (n = 172, 2.7% vs. n = 131, 1.90%) (p 0.002). The
numbers of malaria and chikungunya cases were also increasing, although not signiﬁcantly. Two deaths were recorded: visceral leish-
maniasis and sepsis in a Sudanese migrant, and Acinetobacter sp. pneumonia in a patient who had visited Spain. This is the most compre-
hensive study of travel-related illness in Europe in 2009 as compared with 2008. A signiﬁcant increase in travel-related respiratory and
vector-borne infections was observed, highlighting the potential risk for introduction of these diseases into Europe, where competent vec-
tors are present. The number of traveller deaths is probably underestimated. The possible role of the travellers in the emergence of infec-
tious diseases of public health concern is highlighted.
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Introduction
The international circulation of microorganisms, vectors and
infected individuals and animals poses a global public health
threat, and requires attention at the national and interna-
tional levels. In 2009, 12 EuroTravNet sites from nine Euro-
pean countries, also belonging to the global GeoSentinel
surveillance system (http://www.eurotravnet.eu ), contributed
to this study, whose aim was to describe demographic, epi-
demiological and clinical characteristics of ill travellers who
presented in 2009 in order to assess the importance of
infectious diseases that are non-endemic in Europe, but have
the potential for re-introduction. Comparison with 2008 data
[1] was performed when appropriate.
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Patients and Methods
We included patients who presented from 1 January to 31
December 2009 at any of the participating EuroTravNet sites
with a history of international travel and a travel-associated
complaint as judged by the treating physician, as described
previously [2]. Some patients were found to have no morbid-
ity after examination. Reasons for travel were grouped into
eight main categories (Table 1). Speciﬁc diagnoses from a list
of 688 items were grouped into 22 broad syndromes, and
countries of likely exposures were grouped into 13 regions
(Table 1) [1]. Data were analysed with SPSS v16.0 (SPSS,
Chicago, IL, USA). Owing to the absence of a true denomi-
nator, no incidence rates or risk estimates can be calculated.
Rather, proportionate morbidity was used, comparing the
number of cases of a speciﬁc diagnoses or syndrome with all
cases of ill returned travellers seen during the same time
period. Differences in proportionate morbidity between
2009 and 2008 in ill returned travellers seen at EuroTravNet
core sites were tested with Pearson chi-square or Fisher
exact tests. t-Tests were used for continuous variables. A
p-value of <0.01 was chosen to adjust for the large number
of statistical tests performed.
Results
The same core sites contributed patients to the analysis in
2008 and 2009, although the proportionate contribution var-
ied over time in some of the sites (Table 2).
Demographics and patient characteristics
In 2009, 6392 patients with travel-associated health com-
plaints were seen at the participating institutions (n = 6957
in 2008). Information about demographics, reason for travel,
risk level and clinical setting is given in Table 1.
Epidemiology and exposure region of ill travellers
The median times from travel to presentation at a clinic was
12 days (in 2008) and 13 days (in 2009) respectively in trav-
ellers and 2.4 years (2008 and 2009) in those whose reason
for travel was immigration. In both 2008 and 2009, travellers
were most likely exposed in sub-Saharan Africa (25.9% and
25.67%, respectively). In 2009, there was a remarkable
TABLE 1. Demographic characteristics of travellers
Site 2008 2009 p-value
Gender (%)
Female 48.9 50.3
Travel reason (%)
Business 10.5 11.0 <0.001
Immigration 9.4 7.7
Medical tourism 0.1 0.4
Military 0.6 1.0
M/V/AW/R 22.6 20.0
Student 1.3 2.5
Tourism 43.5 45.0
VFR 11.9 12.5
Risk level (%)
Expatriate 6.9 8.6 <0.001
Pre-arranged or
organized travel
22.6 26.6
Risk travela 69.8 63.7
Missing 0.8 1.2
Clinical setting (%)
Immigration only 9.4 7.7 0.001
Seen after travel 82.0 84.4
Seen during travel 8.5 7.9
Inpatient 11.0 14.6 <0.001
Pre-travel advice (%)
Yes 45.4 43.2 <0.001
No 22.4 26.1
Do not know 32.2 30.7
Born in Europe (%)
Yes 76.0 77.5 0.035
Age (years)
Mean 37.4 36.9 0.051
(t-test)25th percentile 27.0 27.0
Median 36.0 35.0
75th percentile 48.0 47.0
Region of exposure, no. (%)
Sub-Saharan Africa 1802 (25.90) 1641 (25.67)
North Africa 330 (4.74) 248 (3.88)
Carribean 115 (1.65) 126 (1.97)
Central America 133 (1.91) 162 (2.53)
South America 470 (6.76) 412 (6.45)
North America 23 (0.33) 117 (1.83)
Middle East 107 (1.54) 96 (1.50)
Northeast Asia 78 (1.12) 52 (0.81)
South Central Asia 676 (9.77) 550 (8.60)
Southeast Asia 631 (9.07) 678 (10.61)
Eastern Europe 114 (1.64) 55 (0.86)
Western Europe 227 (3.26) 291 (4.55)
Cannot be ascertainedb 2201 (31.64) 1908 (29.85)
Other 50 (0.72) 56 (0.88)
Total 6957 (100) 6392 (100)
M/V/AW/R, missionary/volunteer/Aid work/researcher; VFR, visiting friends and
relatives.
aRisk travel: intended to identify travellers who will, by their behaviour, encoun-
ter a substantial number of the risks facing the local population. This classiﬁca-
tion would generally include no pre-booking of accommodation for most or all
nights and/or use of accommodation speciﬁc to budget travellers or those stay-
ing in the house of local residents.
bCountry of exposure is considered to be not ascertainable when: (i) no coun-
try/region was ascertainable by the physician; (ii) when possible exposure
occurred in more than one country and/or in different regions; (iii) when the
diagnosis could not be attributed to a single travel exposure; or (iv) the patient
was found to be healthy.
TABLE 2. Site contribution
Country Site
2008,
N = 6957 (%)
2009,
N = 6392 (%)
Germany 43.5 35.1
Hamburg 21.3 12.6
Munich 22.2 22.5
France 12.9 16.9
Marseilles 5.0 7.8
Paris 7.9 9.1
UK 18.1 16.2
Cambridge 1.8 2.0
London 16.3 14.2
The Netherlands Amsterdam 0.6 10.5
Norway Oslo 7.2 7.4
Switzerland 9.2 6.7
Geneva 6.0 4.6
Zurich 3.2 2.1
Italy Brescia 2.0 3.8
Spain Madrid 6.5 3.4
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increase in the proportion of travellers exposed in North
America (0.33% in 2008 and 1.83% in 2009) and western
Europe (3.26% in 2008 and 4.55% in 2009). The contrary was
true for eastern Europe (1.64% in 2008 and 0.86% in 2009),
North Africa (4.74% in 2008 and 3.88% in 2009) and South
Central Asia (9.77% in 2008 and 8.6% in 2009). Country of
exposure could not be ascertained in 31.64% and 29.85% of
cases in 2008 and in 2009, respectively (Table 1). Region-
speciﬁc proportionate morbidities are presented in Table 3.
Aetiology and clinical picture of travel-related diseases
Deaths. Two deaths were reported in 2009. The ﬁrst was a
32-year-old male with chronic hepatitis B, born in Eritrea
but of Sudanese nationality, who died after 6 days of visceral
leishmaniasis and sepsis. The second was an 86-year-old male
Norwegian with chronic obstructive pulmonary disease and
Parkinson’s disease, who died from Acinetobacter sp. pneumo-
nia 4 days after returning from Spain. Three deaths were
reported in 2008.
Travel-related diseases in Europe. The proportion of patients
suffering from respiratory illnesses increased from 7.8% in
2008 to 11% in 2009 (p <0.001). Most of this increase was
attributable to cases in 2009 of pandemic A(H1N1) inﬂuenza.
Vector-borne disease with potential for re-introduction into
Europe. . The number of malaria, dengue and chikungunya
cases, considered all together, signiﬁcantly increased from
507 (7.3%) to 564 (8.8%) (p <0.001), but most of the
increase concerned dengue cases.
Malaria: The total number of imported malaria cases
increased slightly from 365/6957 (5.2%) to 374/6392 (5.8%)
(p 0.127), with a higher species identiﬁcation rate (9.3% of
unknown species in 2008, and 4.3% in 2009). Plasmodium
falciparum was the most commonly reported species (68.2%
in 2008, 74.3% in 2009). We observed a slight but non-signif-
icant increase in malaria from South America, particularly in
military patients with Plasmodium vivax malaria coming from
French Guyana and presenting at the Marseille clinic (3/7 in
2008 and 15/16 in 2009). The number of paediatric malaria
cases rose from nine in 2008 to 28 in 2009, mainly in Italy
(Brescia) and France. Pre-travel encounter was registered for
32% of all malaria patients observed in 2008 and 2009. Com-
plicated malaria cases numbered 12 in 2008 and 14 in 2009
(20 adults and six children overall). Adult patients were
European travellers (n = 12) or expatriates (n = 4) and
migrants (n = 4). Six cases occurred in children: two immi-
grants and four children born in Europe who were visiting
friends and relatives (VFR). They were mainly exposed in
West Africa (Burkina Faso, Ghana, Guinea (two cases), and
Nigeria) and Malawi.
Dengue: Dengue was the second most frequent cause of
fever among ill returning travellers, with 172/6392 cases
(2.7%) in 2009 (no dengue haemorrhagic fever/dengue shock
syndrome), a signiﬁcant increase as compared with 2008
(p 0.002). Of those, 115 cases (67%) were observed in tour-
ists, a similar proportion to that recorded in 2008 (80/131;
61%). Most 2009 cases were imported from the Netherlands
Antilles and Suriname or from Thailand and Vietnam.
Chikungunya: The total number of patients with imported
chikungunya showed a non-signiﬁcant increasing trend from
12/6957 (0.2%) in 2008 to 18/6392 (0.3%) in 2009 (p 0.184).
Most patients were exposed in Southeast Asia (Thailand,
TABLE 3. Top diagnoses by region of exposure, 2008–2009
Top ﬁve diagnoses 2008, no. (%) 2009, no. (%)
Sub-Saharan Africa
N = 1802, N = 1641
Malaria 318 (18) 321 (20)
Viral syndrome, no rash 146 (8) 99 (6)
Diarrhoea, acute unspeciﬁed 113 (6) 118 (7)
Schistosomiasis 79 (4) 97 (6)
Diarrhoea, acute bacterial 52 (3) 40 (2)
Southeast Asia
N = 631, N = 678
Dengue 60 (10) 65 (10)
Diarrhoea, acute unspeciﬁed 58 (9) 52 (8)
Viral syndrome, no rash 64 (10) 43 (6)
Diarrhoea, chronic unknown 34 (5) 29 (4)
CLM, hookworm-related 24 (4) 38 (6)
South Central Asia
N = 676, N = 550
Giardia 74 (11) 62 (11)
Diarrhoea, acute unspeciﬁed 71 (11) 52 (9)
Diarrhoea, chronic unknown 40 (6) 36 (7)
Campylobacter 25 (4) 37 (7)
Viral syndrome, no rash 41 (6) 21 (4)
South Americaa
N = 351, N = 374
Diarrhoea, acute unspeciﬁed 23 (7) 30 (8)
Viral syndrome, no rash 26 (7) 12 (3)
Diarrhoea, chronic unknown 19 (5) 19 (5)
CLM, hookworm-related 17 (5) 20 (5)
Malaria 12 (3) 21 (6)
North Africa
N = 330, N = 248
Diarrhoea, acute unspeciﬁed 54 (16) 38 (15)
Diarrhoea, chronic unknown 25 (8) 16 (6)
Irritable bowel syndrome,
post-infectious
21 (6) 18 (7)
Animal bite requiring rabies PEP 19 (6) 14 (6)
Gastroenteritisb 24 (7) 5 (2)
Europe
N = 341, N = 346
Gastroenteritisb 26 (8) 10 (3
Inﬂuenza-like illnessb 1 (0) 34 (10)
Inﬂuenza, novel H1N1b 0 (0) 33 (10)
Pneumonia, bacterial (lobar) 21 (6) 11 (3)
Diarrhoea, acute unspeciﬁed 17 (5) 14 (4)
All regionsc
N = 6957, N = 6392
No morbidity found 1056 (15) 977 (15)
Diarrhoea, acute unspeciﬁed 423 (6) 375 (6)
Malaria 365 (5) 374 (6)
Viral syndrome (no rash) 434 (6) 266 (4)
Diarrhoea, chronic unknown 265 (4) 226 (4)
CLM, cutaneous larva migrans; PEP, post-exposure prophylaxis.
aBolivians screened for Chagas disease in Europe are excluded.
bSigniﬁcant at p <0.01.
cIncludes 1773 patients seen only for screening, with no morbidity found and
region of exposure not ascertained.
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Singapore, Malaysia, and Indonesia), South Central Asia (India
and the Maldives), and the Indian Ocean Islands (La Reunion).
Emerging diseases. Pandemic A(H1N1) inﬂuenza: The pandemic
A(H1N1) inﬂuenza was the main determinant of the increase
in respiratory illnesses observed in 2009. As many as 171/
6392 cases of inﬂuenza-like illness (2.3%) and 83/6392 cases
of conﬁrmed pandemic A(H1N1) inﬂuenza (1.1%) were
observed, mainly in students and tourists returning from the
USA, the UK, Spain, Argentina, and Mexico, in decreasing
order. The ﬁrst case of pandemic A(H1N1) inﬂuenza in the
EuroTravNet network was reported on 28 April 2010 in a
tourist from Mexico (Fig. 1). Inﬂuenza-like illnesses that were
not conﬁrmed as pandemic A(H1N1) inﬂuenza were seen in
patients exposed in the USA, Spain, and the UK, although
there were also cases from Thailand and India.
Chagas disease: The number of reported new Chagas
cases, detected by serology, decreased from 94/6957 (1.4%)
to 30/6392 (0.5%) (p £0.001).
Chronic diseases. There was a signiﬁcant increase in the pro-
portion of reported tuberculosis (TB) cases, from 1.5% in
2008 to 2.1% in 2009 (p 0.003), primarily from the clinic in
Brescia. Human immunodeﬁciency virus (HIV)/AIDS repre-
sented the most frequent chronic diagnosis, followed by
active TB and latent TB. Of the HIV/AIDS cases, 217 were
migrants, and 76 were non-migrants. Arriving immigrants
accounted for 163 cases, and the remaining cases were
mainly VFR travellers.
Miscellaneous. In 2009, 19 cases of cutaneous leishmaniasis
and four cases of visceral leishmaniasis were reported, as
compared with 12 cases of cutaneous leishmaniasis and two
cases of visceral leishmaniasis in 2008.
Diseases acquired in Europe. As many as 346 (5.4%) travel-
related diseases were observed following travel within Eur-
ope in 2009, a similar number to that in 2008 (n = 341/5967,
4.9%). However, the exposure shifted slightly away from
immigrants and VFR travellers from eastern Europe (4% and
9% in 2009, from 8% and 25% in 2008). The main European
countries of exposure were Germany (n = 115), Spain
(n = 64), the UK (n = 38), Italy (n = 25), and France
(n = 12). Respiratory illness (p 0.003), including pandemic A
(H1N1) inﬂuenza, and acute diarrhoea (p 0.010) were
reported more often in 2009 than in 2008.
Discussion
Travel-related illnesses may have important public health
consequences if conditions for re-introduction of diseases
are met [3]. In our dataset, in 2008 and 2009, ﬁve deaths
were reported. This is probably an underestimate of the
mortality burden, as it does not include patients who died
overseas, and patients who die may be more likely to be
seen in other types of clinic.
During the last few years, the number of imported malaria
cases in Europe has decreased, possibly reﬂecting malaria
control activities in endemic countries [4,5]. However,
malaria in Europe remains an important travel medicine
issue, given the large number of imported cases [6]. More-
over, there is potential for the reappearance of malaria in
countries where it was previously eradicated, and limited
outbreaks do occur in Europe, where Anopheles mosquitoes
are still present, mainly in the Mediterranean area [7], mak-
ing the slight, although not statistically signiﬁcant, increase
observed in our dataset in 2009 a phenomenon that requires
attention. In August 2006, one case of indigenous P. vivax
FIG. 1. Pandemic A(H1N1) incident
cases.
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malaria was diagnosed in Corsica [8], and in October 2010,
another was diagnosed in Aragon, Spain, where the vector,
Anopheles atroparvus, is present [9].
Dengue is the second most common cause of fever in
returned ill travellers [10]. The increase in the number of
dengue cases observed in 2009 is mainly attributable to the
increased participation of the clinic in Amsterdam, with
patients coming from the Netherlands Antilles and Suriname,
and to an increase in the numbers of patients coming from
Thailand and Vietnam, where dengue outbreaks in 2009 were
reported [11,12]. In Mediterranean countries, the presence
of Aedes albopictus can facilitate autochthonous cases [3]. In
August 2010, a case of dengue fever acquired in southern
Croatia in a traveller from Germany was reported [13], and
in September 2010 two cases of autochthonous dengue fever
were diagnosed in metropolitan France (Nice) for the ﬁrst
time. This strongly suggests that local transmission of dengue
is ongoing [14]. Increased surveillance for dengue with mos-
quito control and increased vigilance by health professionals
is needed [15].
Chikungunya remains an important global public health
problem, with several outbreaks occurring worldwide, such
as in Malaysia and Thailand in 2009. Chikungunya activity is
ongoing in the French island of Reunion [16]. Since the
1980s, A. albopictus has spread worldwide, including to south-
ern Europe [17]. After the Italian outbreak in 2007 [3], two
autochthonous cases of chikungunya fever were reported in
France, in September 2010 [18]. Climate changes, urbaniza-
tion and international transport may facilitate the enlarge-
ment of areas endemic for chikungunya and other vector-
transmitted infections, posing a threat to global public health
even in areas previously considered to be safe, such as
Europe. The presence of adequate vectors in Europe may
favour the stable introduction of vector-borne diseases [19].
Chagas disease is a potentially life-threatening illness,
affecting over 10 million people, originating mainly from Latin
America. Although the vector (Triatominae spp.) is not pres-
ent on the European continent, the chronic nature of the
disease, together with the migration ﬂow from endemic
countries, can have a public health impact in Europe [20], as
it is potentially transmissible to the autochthonous popula-
tion through contaminated blood products, and also causes
congenital and chronic diseases [21]. Owing to its historical
links with Latin America, Spain reports the highest number
of Chagas cases in Europe. A moderate decrease in the num-
ber of cases of Chagas infection detected by serology was
observed in 2009. This is probably attributable to the 2009
economic crisis, which has forced many migrants to return
to their country origin, or to a cohort effect, after much of
the Bolivian migrant community in Madrid was screened in
2008. Efforts are needed to improve knowledge of Chagas
disease among physicians [22] and to develop screening and
control in blood banks, organ donation, and at-risk pregnant
women.
Pandemic A(H1N1) inﬂuenza was ﬁrst detected in the
USA on 15 April 2009, and the WHO declared it a Public
Health Emergency of International Concern on 25 April
2009. Recommendations to countries to intensify surveillance
were soon issued [23]. In our dataset, after the ﬁrst case,
reported on 28 April in a European traveller returning from
Mexico, the number of conﬁrmed reported cases peaked in
July 2009. Pandemic A(H1N1) inﬂuenza cases were primarily
diagnosed, in decreasing order, in students and tourists
exposed in the USA, the UK, Spain, Argentina, and Mexico.
As pandemic A(H1N1) inﬂuenza became a global problem,
we observed a progressive decrease in the number of cases
reported in Europe, potentially reﬂecting the widespread
management of these patients at various levels of the Euro-
pean health systems, as well as the possibility that new cases
of pandemic A(H1N1) inﬂuenza were now more likely to be
acquired locally rather than through travel. Our data under-
line the usefulness of surveillance networks to monitor an
unexpected epidemic event in Europe. Pandemic A(H1N1)
inﬂuenza greatly affected the proﬁle of the patients observed
in our network, with a shift to travellers and students
returning from North America [24].
The small increase in the number of TB cases may reﬂect
the changing composition of newly arriving migrant communi-
ties, particularly Pakistani and Indian migrants, in Brescia, Italy,
a popular destination for migrants in Italy. The impact of
imported TB on the local epidemiology may vary from coun-
try to country [25]. These numbers may change from year to
year as migration patterns change, and could therefore be a
marker for the possibility of other illnesses in migrants.
Most of the cases of HIV/AIDS in our study were in immi-
grants. The long incubation periods of HIV/AIDS and TB
make it very difﬁcult to ascribe these infections to a speciﬁc
travel episode or to an infectious condition existing before
travel in migrants [26,27]. Pre-travel and post-travel advice
by infectious disease specialists will be important, as the
prevalence of HIV infection is expected to rise as AIDS-
related mortality is decreasing [28].
We recognize the following limitations that may possibly
make time comparisons less accurate. (i) The relative contri-
butions of participating centres varied from 2008 to 2009.
This means that the 2009 proportionate morbidity presents
a more legitimate baseline than counts. (ii) As EuroTravNet
represents a sample of travellers who sought medical care,
the incidence and risk of returning with any given diagnosis
cannot be calculated. However, proportionate morbidity can
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be calculated to compare relative frequencies of illness in ill
returned travellers. (iii) Our analysis could not capture all
febrile illness in travellers, because infections that have short
incubation periods may manifest during travel. The patient
intake at each site reﬂects local or national differences in the
composition of the travelling population, the distribution of
the travel destinations, and access to medical care. However,
we are conﬁdent that the large sample size, the European
heterogeneous mix of sites and patients and the quality and
consistency of the collected data compensated for biases and
provide useful information.
Conclusions
The timely and accurate reporting of ad hoc surveillance net-
works such as EuroTravNet will supplement and reinforce
regular routine disease reporting, and serve as a sentinel for
emerging infectious diseases. Travellers played an important
role in the spread of pandemic A(H1N1) inﬂuenza, as has
already occurred in the past for other airborne infections
(i.e. SARS). Vector-borne infections, such as malaria, chi-
kungunya and dengue, need ongoing surveillance as global
warming, urbanization and international transport may facili-
tate the enlargement of endemic areas. Secondary cases may
be expected, and have already been reported in Europe.
Increased surveillance for mosquito control and increased
vigilance by health professionals are needed.
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